Induction of Non-Canonical Ferroptosis by Targeting Clusters Suppresses Glioblastoma

Kai Cao,Liyuan Xue,Kaidi Luo,Wendi Huo,Panpan Ruan,Dongfang Xia,Xiuxiu Yao,Wencong Zhao,Liang Gao,Xueyun Gao
DOI: https://doi.org/10.3390/pharmaceutics16091205
IF: 6.525
2024-09-14
Pharmaceutics
Abstract:Glioblastoma multiforme (GBM) is the most aggressive brain tumor. There is a pressing need to develop novel treatment strategies due to the poor targeting effect of current therapeutics. Here, a gold cluster coated with optimized GBM-targeting peptide is engineered, namely NA. NA can efficiently target GBM both in vitro and in vivo. Interestingly, the uptake of NA significantly sensitizes GBM cells to ferroptosis, a form of programmed cell death that can bypass the tumor resistance to apoptosis. This effect is exerted through regulating the HO-1-dependent iron ion metabolism, which is the non-canonical pathway of ferroptosis. The combined treatment of a ferroptosis inducer and NA profoundly inhibited tumor growth in both the GBM spheroid model and a syngeneic mouse model with enhanced ferroptosis levels and excellent biosafety. Importantly, the infiltration of tumoricidal lymphocytes is also significantly increased within tumor. Therefore, NA presents a potential novel nanomaterial-based strategy for GBM treatment.
pharmacology & pharmacy
What problem does this paper attempt to address?